Current Diabetes Reports

, 11:345 | Cite as

State of the Art of Clinical Islet Transplantation and Novel Protocols of Immunosuppression

Article

Abstract

Clinical islet transplantation has transitioned from curiosity to realistic therapy over the past decade. An estimated 750 patients have undergone intraportal islet-alone transplantation over this period, and a smaller subset received combined islet-kidney transplants. The primary benefit of successful islet transplantation has been to eliminate severe, recurrent hypoglycemia, a problem that has been hard to eliminate by other means in 15% of those with type 1 diabetes. The secondary benefit of independence from insulin has attracted patients, but has had limited sustainability previously, especially with a single-donor graft, but recent results from four independent centers suggest marked improvement in long-term outcome, with 5-year results now approximating solitary pancreas transplantation. Emerging data confirm that islet transplantation can stabilize and reverse several secondary diabetic complications similar to whole pancreas transplantation, but larger, head-to-head trials are needed to compare islet transplantation with best medical therapies. Current goals are to extend durability, and to make islet transplantation more widely available for patients in need. Governmental and health insurance providers in several countries now reimburse islet transplantation as part of clinical care. As the safety of the procedure and of adjunctive immunosuppressive therapies improve, and benefit accrues over potential risk, islet transplantation will be offered earlier in the course of the disease, including newly diagnosed children. The role of islet transplantation in type 2 diabetes has yet to be defined. We review the current status of islet transplantation, and discuss current and future immunosuppressive protocols that will pave the way to more broad application of cellular replacement in diabetes.

Keywords

Islet of Langerhans Transplantation Immunosuppression Diabetes Hypoglycemia Clinical Islet transplantation 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011;60(1):1–8. This current article nicely reviews a series of current efforts to reverse T1DM in patients. PubMedCrossRefGoogle Scholar
  2. 2.
    McCall MD, Toso C, Baetge EE, Shapiro AM. Are stem cells a cure for diabetes? Clin Sci (Lond). 2010;118(2):87–97.CrossRefGoogle Scholar
  3. 3.
    Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes. 1999;48(10):1907–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Eriksson O, Eich T, Sundin A, Tibell A, Tufveson G, Andersson H, et al. Positron emission tomography in clinical islet transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. Am J Transplant. 2009;9(12):2816–24.Google Scholar
  5. 5.
    Harlan DM, Kenyon NS, Korsgren O, Roep BO. Current advances and travails in islet transplantation. Diabetes. 2009;58(10):2175–84.PubMedCrossRefGoogle Scholar
  6. 6.
    • Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation. 2010;89(4):465–71. This article demonstrates that peritransplant treatment of the islet transplant recipient with insulin and heparin can significantly improve the single-donor islet engraftment rate, and provides the first clinical supportive evidence that protection of islets from the IBMIR may improve islet survival, building upon substantial data generated by the Uppsala group in IBMIR research. PubMedCrossRefGoogle Scholar
  7. 7.
    Korsgren O, Lundgren T, Felldin M, Foss A, Isaksson B, Permert J, et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia. 2008;51(2):227–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Korsgren O, Nilsson B. Improving islet transplantation: a road map for a widespread application for the cure of persons with type I diabetes. Curr Opin Organ Transplant. 2009;14(6):683–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med. 2007;356(26):2754–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Rickels MR, Collins HW, Naji A. Amyloid and transplanted islets. N Engl J Med. 2008;359(25):2729. author reply −31.PubMedCrossRefGoogle Scholar
  11. 11.
    Westermark GT, Westermark P, Berne C, Korsgren O. Widespread amyloid deposition in transplanted human pancreatic islets. N Engl J Med. 2008;359(9):977–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Griffin SM, Alderson D, Farndon JR. Comparison of harvesting methods for islet transplantation. Br J Surg. 1986;73(9):712–5.PubMedCrossRefGoogle Scholar
  13. 13.
    • Bellin MD, Kandaswamy R, Parkey J, Zhang HJ, Liu B, Ihm SH et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008;8(11):2463–70. This article provides remarkable data from the Minnesota group on single-donor islet transplantation success in a clinical series of islet transplant recipients, in which T-depletional induction therapy is given, combined with intensive peri-islet transplant management. PubMedCrossRefGoogle Scholar
  14. 14.
    Bellin MD, Sutherland DE, Beilman GJ, Hong-McAtee I, Balamurugan AN, Hering BJ, et al. Similar islet function in islet allotransplant and autotransplant recipients, despite lower islet mass in autotransplants. Transplantation. 2011;91(3):367–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Shapiro AM, Toso C, Koh A, Calne RY, Kin T, O’Gornan D, et al. Alemtuzumab + Tac/MMF substantially improves long-term insulin-independence, and strongly suppresses auto + alloreactivity after clinical islet transplantation. Transplantation. 2010;90:134.CrossRefGoogle Scholar
  16. 16.
    • Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8. This landmark article was the first to demonstrate sustained insulin independence for periods up to 1 year in seven T1DM subjects transplanted with human islets, and immunosuppressed with the “Edmonton Protocol,” with sirolimus, tacrolimus, and an induction anti-interleukin-2 receptor mAb. Important for this success was the transplantation of islets prepared from at least two donor pancreas organs to provide sufficient islet engraftment mass. PubMedCrossRefGoogle Scholar
  17. 17.
    Deng S, Markmann JF, Rickels M, Yeh H, Kim JI, Lian MM, et al. Islet alone versus islet after kidney transplantation: metabolic outcomes and islet graft survival. Transplantation. 2009;88(6):820–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Hammer M, Lammert M, Mejias SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281–90.PubMedCrossRefGoogle Scholar
  19. 19.
    • Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010;16(2):244–8. This article provides a case report of the use of continuous glucose monitoring, in which a patient died as a direct result of sustained and uncontrollable hypoglycemia. Although the “dead-in-bed” syndrome is fortunately rare, it remains a much feared and underestimated aspect of insulin injection treatment in T1DM. PubMedCrossRefGoogle Scholar
  20. 20.
    Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995;18(11):1415.Google Scholar
  21. 21.
    Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57(12):3169–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group, Bethesda, Maryland. Diabetes Care. 1990;13(4):427–33.Google Scholar
  24. 24.
    Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant. 2004;4(12):2018–26.PubMedCrossRefGoogle Scholar
  26. 26.
    Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. Jama. 2003;290(21):2817–23.PubMedCrossRefGoogle Scholar
  27. 27.
    Fiorina P, Gremizzi C, Maffi P, Caldara R, Tavano D, Monti L, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care. 2005;28(6):1358–65.PubMedCrossRefGoogle Scholar
  28. 28.
    Fung MA, Warnock GL, Ao Z, Keown P, Meloche M, Shapiro RJ, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation. 2007;84(1):17–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant. 2005;5(9):2318–23.PubMedCrossRefGoogle Scholar
  30. 30.
    • Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011;91(3):373–8. This article demonstrates that successful islet transplantation can effectively reverse and stabilize risk of secondary diabetic complications in patients receiving islet transplantation. The Vancouver group compared islet recipients to best medical therapy (with optimal insulin, blood pressure, and lipid control) and found that the islet transplant intervention had a more positive impact upon secondary complication risk. The work now justifies a randomized controlled multicenter study. PubMedCrossRefGoogle Scholar
  31. 31.
    Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37(4):413–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Lakey JR, Warnock GL, Shapiro AM, Korbutt GS, Ao Z, Kneteman NM, et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant. 1999;8(3):285–92.PubMedGoogle Scholar
  33. 33.
    Barbaro B, Salehi P, Wang Y, Qi M, Gangemi A, Kuechle J, et al. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation. 2007;84(9):1200–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004;4(3):390–401.PubMedCrossRefGoogle Scholar
  35. 35.
    Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. Jama. 2005;293(7):830–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Low G, Hussein N, Owen RJ, Toso C, Patel VH, Bhargava R, et al. Role of imaging in clinical islet transplantation. Radiographics. 2010;30(2):353–66.PubMedCrossRefGoogle Scholar
  37. 37.
    Froud T, Yrizarry JM, Alejandro R, Ricordi C. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. 2004;13(1):55–9.PubMedGoogle Scholar
  38. 38.
    Villiger P, Ryan EA, Owen R, O’Kelly K, Oberholzer J, Saif FA, et al. Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant. 2005;5(12):2992–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Markmann JF, Deng S, Huang X, Desai NM, Velidedeoglu EH, Lui C, et al. Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg. 2003;237(6):741–9. discussion 9–50.PubMedGoogle Scholar
  40. 40.
    Gangemi A, Salehi P, Hatipoglu B, Martellotto J, Barbaro B, Kuechle JB, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant. 2008;8(6):1250–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010;10(8):1870–80.PubMedCrossRefGoogle Scholar
  42. 42.
    • Burke GW, 3rd, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A. Recurrence of Autoimmunity Following Pancreas Transplantation. Curr Diab Rep. 2011. Recurrence of autoimmunity is a much underappreciated area in transplantation for T1DM. Burke et al. intensively studied evidence for and mechanisms underlying recurrence of autoimmunity following clinical pancreas transplantation, and their work is summarized here. Google Scholar
  43. 43.
    Matsumoto S, Takita M, Chaussabel D, Noguchi H, Shimoda M, Sugimoto K et al. Improving Efficacy of Clinical Islet Transplantation with Iodixanol Based Islet Purification, Thymoglobulin Induction and Blockage of IL-1-beta and TNF-alpha. Cell Transplant. 2011.Google Scholar
  44. 44.
    Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83(1):24–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Merani S, Truong W, Emamaullee JA, Toso C, Knudsen LB, Shapiro AM. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology. 2008;149(9):4322–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Toso C, McCall M, Emamaullee J, Merani S, Davis J, Edgar R, et al. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int. 2010;23(3):259–65.PubMedCrossRefGoogle Scholar
  47. 47.
    • Emamaullee JA, Davis J, Pawlick R, Toso C, Merani S, Cai SX et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes. 2008;57(6):1556–66. Preventing cell death early after islet transplantation may facilitate single-donor islet transplant survival, as illustrated by Emamaullee et al. This paper demonstrates that transplantation of 10% of the usual required islet transplant mass may be sufficient to reverse diabetes in immunodeficient mice transplanted with human islets treated with a caspase inhibitor designed to prevent apoptosis. PubMedCrossRefGoogle Scholar
  48. 48.
    McCall M, Toso C, Emamaullee J, Pawlick R, Edgar R, Davis J et al. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery.Google Scholar
  49. 49.
    Chatenoud L. Chemical immunosuppression in islet transplantation–friend or foe? N Engl J Med. 2008;358(11):1192–3.PubMedCrossRefGoogle Scholar
  50. 50.
    Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest. 2007;117(9):2553–61.PubMedCrossRefGoogle Scholar
  51. 51.
    Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132(2):166–73.PubMedCrossRefGoogle Scholar
  52. 52.
    Wijkstrom M, Kenyon NS, Kirchhof N, Kenyon NM, Mullon C, Lake P, et al. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation. 2004;77(6):827–35.PubMedCrossRefGoogle Scholar
  53. 53.
    • Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010;90(12):1595–601. The San Francisco group report their remarkable calcineurin-free immunosuppressive approaches in islet transplant recipients in which either anti-CD11a (efalizumab) or costimulation blockade with belatacept is given. The importance of these data are that effective immunosuppression can be supplied by regimens that do not contain nephrotoxic and diabetogenic calcineurin inhibitor drugs, and that the absence of tacrolimus can facilitate single-donor islet transplant engraftment and survival. PubMedCrossRefGoogle Scholar
  54. 54.
    Liu C, Noorchashm H, Sutter JA, Naji M, Prak EL, Boyer J, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med. 2007;13(11):1295–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR, et al. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation. 2011;91(6):672–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H, Yonekawa Y, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet. 2005;365(9471):1642–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Sachs DH. Transplant tolerance: bench to bedside–26th annual samuel jason mixter lecture. Arch Surg. 2011;146(5):501–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Adams AB, Shirasugi N, Jones TR, Durham MM, Strobert EA, Cowan S, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005;174(1):542–50.PubMedGoogle Scholar
  59. 59.
    Thompson P, Cardona K, Russell M, Badell IR, Shaffer V, Korbutt G, et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant. 2011;11(5):947–57.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Clinical Islet Transplant ProgramUniversity of AlbertaEdmontonCanada

Personalised recommendations